The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 220.00
Ask: 230.00
Change: 10.00 (4.65%)
Spread: 10.00 (4.545%)
Open: 215.00
High: 234.00
Low: 225.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron Appoints Panmure Gordon as Joint Broker

22 Apr 2016 07:00

RNS Number : 9912V
Faron Pharmaceuticals Oy
22 April 2016
 

 

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Faron Appoints Panmure Gordon as Joint Broker

 

TURKU - FINLAND 22 April 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), a drug discovery and development company, announces today the appointment of Panmure Gordon (UK) Limited ("Panmure Gordon") as Joint Broker to the Company with immediate effect. Whitman Howard will continue to act as Joint Broker to the Company.

- END -

 

For more information, please contact:

 

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone: +358 (50) 577 4807

E-mail: katja.wallenlind@faronpharmaceuticals.com

 

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson, Rebecca Anderson

Phone: +44 207 148 7900

 

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

 

Whitman Howard Limited, Joint Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

 

About Faron Pharmaceuticals Ltd.

 

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Faron Pharmaceuticals Oy is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPUAABRNSASUAR
Date   Source Headline
25th Aug 20217:00 amRNSFirst Patient Dosed in Phase II/III COVID-19 Trial
28th Jul 20217:00 amRNSNotice of Half-Year Report
12th Jul 20217:00 amRNSFaron to Host KOL Webinar on Clever-1 Receptor
22nd Jun 20217:00 amRNSUpdated corporate presentation
14th Jun 202111:05 amRNSSecond Price Monitoring Extn
14th Jun 202111:00 amRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSBexmarilimab granted key US patent
3rd Jun 20217:00 amRNSBexmarilimab results published in CCR
17th May 20217:00 amRNSBexmarilimab shows promising anti-tumour activity
14th May 20217:00 amRNSUS rights to patent related to Traumakine
10th May 20212:30 pmRNSHolding(s) in Company
29th Apr 202112:45 pmRNSGrant of options
23rd Apr 20211:45 pmRNSBoard Change
23rd Apr 20211:45 pmRNSResult of AGM
29th Mar 20217:00 amRNSAppointment of a Broker
25th Mar 20217:45 amRNSExercise of Options
25th Mar 20217:30 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20217:15 amRNSFaron´s Annual Report 2020 published
25th Mar 20217:00 amRNSFinancial statement January 1 to December 31 2020
22nd Mar 20217:00 amRNSBexmarilimab (Clevegen) development update
11th Mar 20217:00 amRNSFaron to Present at Oppenheimer Conference
2nd Mar 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
25th Feb 20217:00 amRNSNotice of Full-Year Results and Annual Report
17th Feb 20214:30 pmRNSHolding(s) in Company
12th Feb 20213:00 pmRNSRegistration of Placing Shares
12th Feb 20217:00 amRNSResults of Placing and Issue Price
11th Feb 20214:30 pmRNSProposed Issue and Placing of Shares
26th Jan 20217:00 amRNSUpdate on TRAUMAKINE development
20th Jan 20212:06 pmRNSSecond Price Monitoring Extn
20th Jan 20212:01 pmRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSBexmarilimab (Clevegen) development update
18th Jan 20212:05 pmRNSSecond Price Monitoring Extn
18th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Jan 202111:06 amRNSSecond Price Monitoring Extn
18th Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20217:00 amRNSUS Department of Defense to support TRAUMAKINE
4th Jan 20217:00 amRNSFaron to Present at H.C. Wainwright
21st Dec 20207:00 amRNSFaron’s financial calendar for 2021
10th Dec 20207:00 amRNSPresents at ESMO Immuno-Oncology Virtual Congress
23rd Nov 20207:30 amRNSTo Participate in Upcoming Investor Conferences
23rd Nov 20207:00 amRNSBexmarilimab (Clevegen) development update
20th Nov 20207:00 amRNSIssue of Equity
16th Oct 202011:35 amRNSFirst Results from WHO Solidarity Trial
14th Oct 20202:15 pmRNSGrant of options
30th Sep 20209:45 amRNSHolding(s) in Company
24th Sep 20207:15 amRNSExercise of options
24th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSMATINS trial data presented at ESMO
9th Sep 202012:00 pmRNSFaron to Present at H.C. Wainwright Conference
27th Aug 20207:00 amRNSNotice of Half-Year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.